Genentech will be granted an exclusive license to develop and commercialize the degrader worldwide, and will be fully responsible for the development and commercialization costs.
The study concluded that elevated levels of two proteins help predict how a person will recover from a traumatic brain injury (TBI), providing important information to determine appropriate care
The OAI classification implies that the US FDA may withhold approval of any pending product applications or supplements filed from this facility till the outstanding observations are resolved
The decision is based on the outcome of a prespecified interim analysis of the Phase 3 AMEERA-5 trial
The Supervisory Board has unanimously decided to propose Roy Jakobs as the next President and CEO of Royal Philips to its General Meeting of Shareholders.
The Trial, the first of its kind in Israel, recently obtained approval from the Israeli Ministry of Health and is preparing for participant recruitment.
ELCYS is the only FDA-approved cysteine hydrochloride injection on the market for use as an additive to amino acid solutions
The card-to-cloud device was launched into the U.S. and many other markets and is designed to work without an embedded communications module.
Collaboration focuses on developing and implementing real-world research to drive patient access to cancer medicines
QIAstat-Dx Viral Vesicular Panel tests for six pathogens that produce similar symptoms
Subscribe To Our Newsletter & Stay Updated
